Orthogonal Thinker Takes Steps Towards Patenting Psilocybin Product

Biotech holding company Orthogonal Thinker, Inc. said that it has completed filing a provisional application for the Company’s flagship natural product, Psilly. The provisional application is a legal document filed in the United States Patent and Trademark Office (USPTO), that establishes an early filing date. It does not mature into an issued patent unless the applicant files a regular non-provisional patent application within one year.
“Filing this application allows us to move forward with expanding access to an improved version of psilocin that is not yet available on the market,” said Jason Hobson, CEO of Orthogonal. “This provides us further opportunity to strengthen relationships with organizations across the world who are on the forefront of psychedelic research as we continue to seek partners aligned with our mission to provide holistic wellness solutions. We look forward to sharing our cutting-edge technology to further therapeutic and medical innovations in healthcare. ”
Psilly is Othogonal’s proprietary psilocybin product. The company says that Psilly differs from other psilocybin products in development as it consists of a proprietary formula that uses natural, rather than biosynthetic, alkaloids. According to Wikipedia, alkaloids are produced by a large variety of organisms including bacteria, fungi, plants, and animals. Alkaloids possess psychotropic effects like psilocin and stimulant effects like caffeine.  Although alkaloids act on a diversity of metabolic systems in humans and other animals, they almost uniformly evoke a bitter taste.
The company said that some of the more than $5 million in total seed capital that the company recently raised were allocated to pursue the development and intellectual property protection on Psilly. PsillyLife is the Orthogonal’s lifestyle brand and was conceived to promote education and awareness surrounding the benefits of psilocybin to a worldwide audience.
Potential Patient Population
According to the Centers for Disease Control and Prevention (CDC), antidepressant use in the U.S. continues to grow. Nearly eight percent of the U.S. population took antidepressants between 1999–2002. Between 2011–2014, that number increased to almost 13% of the U.S. public. The global antidepressant and anti-anxiety drugs market is estimated to have reached $12.16bn in 2018. In 2018, the SSRIs segment held 26% of the global antidepressant and anti-anxiety drugs market.

Debra Borchardt

Debra Borchardt is the Co-Founder, and Executive Editor of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Master's degree in Business Journalism from New York University.


One comment

  • James

    May 2, 2020 at 9:47 am

    I like the fact this will never accepted business as usual World

    Because the world thought is vehemently opposed to magic mushrooms through ignorance and lack of education

    Where the word drug simply comes to their mind and as such are so out of touch with this area of transcendence.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.